STOCK MARKET BSE NSE

Zydus in pact with Pieris for drug development

Zydus Cadila has signed a drug development and commercialisation pact with Germany-based Pieris AG to develop a new therapeutic protein molecule — Anticalin.

Published: 17th October 2013 06:00 AM  |   Last Updated: 17th October 2013 12:36 AM   |  A+A-

Zydus Cadila has signed a drug development and commercialisation pact with Germany-based Pieris AG to develop a new therapeutic protein molecule — Anticalin.

The collaboration combines Pieris’ drug discovery and early development capabilities with Zydus’ expertise in biologics development, regulatory affairs and biologics manufacturing, Zydus said.

“Under the terms of agreement, Zydus will take the lead in advancing Anticalin drug candidates through preclinical development and into clinincal development...” it added.

Zydus has been granted exclusive marketing rights in India and several other emerging markets, while Pieris retains exclusive marketing rights in key developed markets.

“Collaborating with established biotech companies on differentiated drug candidates is an important component of Zydus' ongoing transformation into an innovation-led global healthcare provider and we are pleased to add Anticalin to our novel biologics pipeline,” said R Patel, CMD, Zydus Group.

The two companies said the most advanced programme in their collaboration is PRS-110, a target, which is increasingly becoming validated across a broad spectrum of tumours.

“This collaboration will allow Pieris to unlock value on a global scale on a cost-effective manner, significantly expanding the number of proprietary Anticalin programmes we can advance into clinical trials,” said Stephen Yoder, CEO, Pieris.

Through the collaboration, the companies seek to develop candidates to proof-of-concept and will explore out-licensing opportunities in Pieris’ territories.

“The companies will share licensing revenues on mutually agreed upon terms,” it added.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp